Menu Search
Equities

WuXi XDC Cayman Inc

2268:HKG

WuXi XDC Cayman Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)24.55
  • Today's Change-1.45 / -5.58%
  • Shares traded5.01m
  • 1 Year change-12.01%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year WuXi XDC Cayman Inc grew revenues 114.44% from 990.42m to 2.12bn while net income improved 82.07% from 155.73m to 283.54m.
Gross margin30.96%
Net profit margin21.27%
Operating margin25.40%
Return on assets11.88%
Return on equity15.46%
Return on investment15.43%
More ▼

Cash flow in CNYView more

In 2023, WuXi XDC Cayman Inc increased its cash reserves by 1,108.33%, or 3.71bn. Cash Flow from Financing totalled 3.52bn or 165.84% of revenues. In addition the company generated 332.85m in cash from operations while cash used for investing totalled 91.23m.
Cash flow per share0.6427
Price/Cash flow per share42.88
Book value per share5.37
Tangible book value per share5.13
More ▼

Balance sheet in CNYView more

WuXi XDC Cayman Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio4.13
Quick ratio4.02
Total debt/total equity0.0115
Total debt/total capital0.0113
More ▼

Growth rates in CNY

Year on year, growth in earnings per share excluding extraordinary items increased 99.04%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		145.28
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.